Format

Send to

Choose Destination
J Surg Oncol. 2012 Sep 15;106(4):386-92. doi: 10.1002/jso.23095. Epub 2012 Mar 15.

High expression of CX3CL1 by tumor cells correlates with a good prognosis and increased tumor-infiltrating CD8+ T cells, natural killer cells, and dendritic cells in breast carcinoma.

Author information

1
Department of Surgery, Chonnam National University Medical School and Research Institute of Medical Sciences, Gwangju, Republic of Korea.

Abstract

BACKGROUND:

CX3CL1 is the only CX3C chemokine that can chemoattract T cells, natural killer (NK) cells, and dendritic cells (DCs). The role of CX3CL1 in breast carcinoma remains unknown.

METHODS:

Immunohistochemical staining for CX3CL1, CD8, CD57, and CD1a was performed on 204 breast carcinoma specimens using tissue microarray blocks to determine whether CX3CL1 expression correlated with a good prognosis and antitumor immunity.

RESULTS:

The number of stromal CD8+ T cells, intratumoral CD1a+ DCs, and stromal CD57+ NK cells were significantly increased in the high CX3CL1 expression group compared with those in the low CX3CL1expression group. Patients with high CX3CL1 expression had a significantly better disease-free and overall survival than those with low CX3CL1 expression (P=0.002 and P<0.001, respectively). CX3CL1 expression was identified as one of the independent prognostic factors for disease-free and overall survival (P=0.046 and P=0.010, respectively).

CONCLUSION:

The expression of CX3CL1 by tumor cells appears to enhance the recruitment of CD8+ T cells, CD57+ NK cells, and CD1a+ DCs, thereby bringing about a better prognosis in breast carcinoma. CX3CL1 is a new prognostic biomarker and may be a novel candidate for development of a more effective therapeutic strategy for breast carcinoma.

PMID:
22422195
DOI:
10.1002/jso.23095
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center